MFDS Approves 'NJMO', a New Drug for Cold Agglutinin Disease Treatment
The Ministry of Food and Drug Safety approved Sanofi-Aventis Korea's rare and new drug for cold agglutinin disease treatment, 'Nzyomo (Sutimlimab),' on the 12th.
![Mechanism of action of NJM. [Provided by Sanofi Aventis Korea]](http://www.asiae.co.kr/news/img_view.htm?img=2023071214291595140_1689139755.jpg)
This drug is used for the treatment of hemolysis in adult patients with cold agglutinin disease, a type of autoimmune hemolytic anemia (AIHA) in which red blood cells agglutinate and cause hemolysis at temperatures below normal body temperature.
Hot Picks Today
As Samsung Falters, Chinese DRAM Surges: CXMT Returns to Profit in Just One Year
- "Most Americans Didn't Want This"... Americans Lose 60 Trillion Won to Soaring Fuel Costs
- Man in His 30s Dies After Assaulting Father and Falling from Yongin Apartment
- Samsung Union Member Sparks Controversy With Telegram Post: "Let's Push KOSPI Down to 5,000"
- "Why Make Things Like This?" Foreign Media Highlights Bizarre Phenomenon Spreading in Korea
Nzyomo is an IgG4 monoclonal antibody (mAb) that binds to the complement (a protein or glycoprotein in serum acting on the immune system) protein C1s, inhibiting the activation process of the complement and thereby suppressing hemolysis.
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
